Vanguard Group’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-623,488
Closed -$69.3K 4613
2022
Q4
$69.3K Sell
623,488
-8,279
-1% -$5.28K ﹤0.01% 4420
2022
Q3
$669K Hold
631,767
﹤0.01% 4133
2022
Q2
$1.18M Hold
631,767
﹤0.01% 4027
2022
Q1
$2.26M Buy
631,767
+119,929
+23% +$589K ﹤0.01% 3907
2021
Q4
$4.41M Buy
511,838
+63,384
+14% +$403K ﹤0.01% 3683
2021
Q3
$3.41M Buy
448,454
+20,500
+5% +$173K ﹤0.01% 3863
2021
Q2
$2.84M Sell
427,954
-206,948
-33% -$1.3M ﹤0.01% 3856
2021
Q1
$7.68M Buy
+634,902
New +$12.6M ﹤0.01% 3306

Other funds holding LHDX

Vanguard Group's LHDX Position: Q1 2023 in Review

Vanguard Group sold out of Lucira Health, Inc. Common Stock (LHDX) in Q1 2023, closing a stake of 623,488 shares — an estimated $69.3K sold.

Vanguard Group first reported a position in LHDX in Q1 2021 and held it in 8 quarters. The position peaked at $7.68M in Q1 2021. 6 funds tracked by Wall St. Rank hold LHDX as of Q1 2023.

  • Vanguard Group reported no remaining Lucira Health, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 623,488 Lucira Health, Inc. Common Stock shares in Q1 2023, an estimated $69.3K.
  • Vanguard Group first reported a position in Lucira Health, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
  • Vanguard Group's Lucira Health, Inc. Common Stock position peaked at $7.68M in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.